Ocular Analyzes Particulates Root Cause After Whiffing With Steel Blade
Ocular takes another swing at resolving the manufacturing issues that resulted in a complete response letter for its Dextenza.
You may also be interested in...
A new approach, total dedication and lots of practice made a difference for the Massachusetts start-up after FDA approval was twice deferred over manufacturing quality concerns.
The latest drug development news and highlights from our US FDA Performance Tracker.
Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.